ROBERT C. LASKOWSKI
LAW OFFICE
SUITE 600
520 S.W. YAMHILL STREET
PORTLAND, OREGON 97204-1329

TELEPHONE 503-241-0780
FACSIMILE 503-227-2980
EMAIL RCL@ROBLAW.US

November 5, 2014

OTC Markets Group, Inc.
304 Hudson Street
2nd Floor
New York, New York 10013

LIFELINE BIOTECHNOLOGIES, INC.
ANNUAL REPORTS DATED NOVEMBER 5, 2014
FOR THE FISCAL YEARS ENDED DECEMBER 31, 2012 AND 2013

Ladies and Gentlemen:

You are entitled to rely on this letter in determining whether Lifeline Biotechnoloogies, Inc. *("Company")* has made adequate current information publicly available within the meaning of Rule 144 (c)(2) under the Securities Act of 1933, as amended *("Securities Act")*.

The undersigned is a resident of the United States. Our office has been engaged by the Company to be its corporate and securities counsel. Our services include preparing or reviewing disclosure information and press releases, interfacing with the chief financial officer and independent accountants, and giving general legal advice to management.

We have examined such corporate records and other documents and have asked such questions of law as we have considered necessary or appropriate for the purpose of writing this letter. We have relied on publicly available information from the Secretary of State of the State of Nevada and information obtained from the Company's officers and directors. We believe the sources I have relied upon are reliable.

Our letter relates to the laws of the United States, specifically the Securities Act and the corporate laws of the State of Nevada. The undersigned is member in good standing of the bar of the State of Oregon since 1971 and is permitted to practice before the Securities and Exchange Commission *("SEC")* and the undersigned has not been prohibited from practice thereunder.

The Company is not a reporting issuer under the Securities Exchange Act of 1934 *("Exchange Act")* and, therefore, does not file periodic reports with the SEC. We have reviewed publicly available information relating to the Company posted through the OTC Disclosure and News Service and the Issuer's Annual Report dated November 4, 2014 for the fiscal years ended December 31, 2012 and 2013 *("Report")* posted through the OTC Disclosure and News Service.

The Report constitutes, in our opinion, adequate current public information concerning the Company's securities and is available within the meaning of Rule 144(c)(2) under the Securities Act. It includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the securities under Rule 15c2-11 under the Exchange Act and complies as to form with the OTC Pink Basic Disclosure Guidelines v1.1 April 25, 2013, which are located on the Internet at www.otcmarkets.com and been posted through the OTC Disclosure & News Service.

The person responsible for the preparation of the financial statements contained in the Information Statement and the Interim Report was Fred Schiemann, CPA who is qualified to prepare the financial statements. The financial statements included in the Information Statement have not been audited.

The Company's transfer agent is World Wide Stock Transfer, which is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information Statement was to contact the transfer agent and receive written confirmation as to the number of outstanding shares.

The undersigned has personally met with management and a majority of the directors of the Company. The undersigned has reviewed the Report. The undersigned discussed the disclosed information with management and a majority of the directors of the Company.

To the best of my knowledge, after inquiry of management and the directors of the Company, no officer, director or 5% or greater holder of the outstanding securities of the Company, or counsel, is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

We have compiled and list below the names of each executive officer, director, general partner and other control persons of the Company and promoter, finder, consultant or any other advisor of the Company who assisted, prepared or provided information with respect to the Company's disclosure or who received securities as consideration for services rendered to the Company and the following information related to each: (i) their full name, (ii) their business address, (iii) the number and class of the Company's securities beneficially owned by each of them and (iv) with respect to each of the securities described in the preceding clause whether or not the certificate or other document that evidences the securities contains a legend stating that the securities have not been registered under the Securities Act and setting forth or referring to restrictions on transferability and sale of the securities. For purpose of this letter, the term "control person" includes (i) any person controlling, under common control with, or controlled by, the Company or (ii) any person who obtained securities of the Company in connection with a

negotiation with the Company within the three-year period prior to the date of the opinion. With respect to any of the Company's control persons that is an entity and any parent entity of any control person, this letter provides the information for each control person of such entity or parent entity.

Jim Holmes Title: Chief Executive Officer and director.
1325 Airmotive Way, Suite 175
Reno, NV 89502

Common Stock beneficially owned: 181,666,669 shares. All shares of Common Stock beneficially owned are "restricted securities" under the Securities Act of 1933, as amended.

Louis G. Keith, M.D Title: Medical Director and director

Common Stock beneficially owned: 160,333,336 shares. All shares of Common Stock beneficially owned are "restricted securities" under the Securities Act of 1933, as amended.

Fred Schiemann, CPA Title: Chief Financial Officer
429 W. Plumb Lane
Reno, NV 89502

No Common Stock beneficially owned.

The undersigned has made inquiry of each of the persons listed above, persons engaged in promotional activities regarding the Company, and persons owning more than ten percent (10%) of the Company's Common Stock *(collectively, the "Insiders"),* and based upon such inquiries and other available information, any sales of Common Stock by Insiders within the twelve-month period prior to the opinion have been made in compliance with Rule 144, including, without limitation, any required filings of Form 144, and nothing has come to the attention of counsel indicating that any of the Insiders is in possession of any material non-public information regarding the Company or the Securities that would prohibit any of them from buying or selling the Securities under Rules 10b-5 or 10b5-1 under the Exchange Act.

No person other than OTC Markets Group, Inc. is entitled to rely on this letter. However, the undersigned hereby grants OTC Markets Group, Inc. full and complete permission and rights to publish this letter in the OTC Disclosure and News Service for viewing by the public and regulators.

Very truly yours,

Robert Laskowski

Robert C. Laskowski